Gimeracil: Indication, Dosage, Side Effect, Precaution

This information is not country-specific. Please refer to the Malaysia prescribing information.

Generic Medicine Info

Indications and Dosage

Oral
Resectable gastric carcinoma

Adult: In combination with tegafur and oteracil potassium: 40 mg/m² BSA bid for 7 days pre-operatively and for 15 days after operation starting on day 15 after operation.

Contraindications

Hypersensitivity, Pregnancy and breast-feeding.

Special Precautions

Cardiac, renal or hepatic impairment. Monitor CBC durring chemotherapy.

Adverse Reactions

Fatigue, diarrhoea, constipation, sore mouth, hair thining, rash, loss of appetite, change in taste, headaches, insomnia, brittle nails, photosensitivity, confusion, drowsiness.
Potentially Fatal: Bone marrow suppression during chemotherapy.

Drug Interactions

May cause changes in INR readings when used with warfarin. May raise serum phenytoin levels when used concurrently.

Action

Description:
Mechanism of Action: Gimeracil strongly inhibits dihydropyrimidine dehydrogenase, and inhibits 5-FU degradation approximately 180 times more effectively than uracil in vitro. Coadministration of gimeracil and tegafur markedly increases the antitumor activity of tegafur.

MIMS Class

Cytotoxic Chemotherapy

Disclaimer: This information is independently developed by MIMS based on Gimeracil from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com